Stay updated with breaking news from Mol Biol. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
First Phase III results in breast cancer for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan Plans for global regulatory submissions underway ...
Positive CHMP opinion based on comprehensive package of analytical, pre-clinical and clinical data Breast and gastric cancers are among most common types of cancer, accounting together for nearly...
Data support ongoing discussions with global health authorities ...
With its nutty flavor and dense nutrient profile, the humble chickpea has captivated palates and nourished civilizations for millennia.
AstraZeneca and Daiichi Sankyo’s ENHERTU showed an objective response rate of 37.1% in the overall population of the DESTINY-PanTumor02 Phase II trial ENHERTU is the first therapy to show... | June 5, 2023